Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
Earnings Data
Report Date
Apr 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.79Last Year’s EPS
0.75Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized materially strong financial performance in 2025 (record revenues >$20B, double-digit organic growth, EPS and margin expansion, and robust free cash flow) with multiple high-growth franchises (EP, WATCHMAN, IO, cardiovascular) and confident 2026 guidance and long-range targets. Challenges were acknowledged — AXIOS product removal affecting Endo H1, ACURATE discontinuation impacting EMEA and Q1, underperformance in urology, a meaningful GAAP litigation charge, and competitive share dynamics in EP — but management provided mitigation paths and timing for resolution (midyear fixes, product launches, tuck-in M&A). Overall, positives (broad-based growth, margin and cash-flow improvement, strong clinical catalysts and strategic deals) significantly outweigh the manageable operational and one-time headwinds.Company Guidance
Record Full-Year Revenue and Strong Organic Growth
Full-year 2025 revenue of $20.74 billion (reported growth +19.9% vs. 2024). Operational revenue for the year grew 19.2% and organic revenue grew 15.8%, exceeding guidance (~15.5%). Q4 2025 operational revenue grew 14.3% and organic revenue grew 12.7% (Q4 reported revenue $5.286 billion, +15.9% reported).
Robust EPS and Margin Expansion
Q4 adjusted EPS $0.80 (+15% vs. prior year) and full-year adjusted EPS $3.06 (+22% vs. prior year). Full-year adjusted operating margin expanded 100 basis points to 28.0% and adjusted gross margin expanded 30 basis points to 70.6%.
Strong Free Cash Flow and Balance Sheet
Full-year free cash flow of $3.659 billion (+38% vs. 2024) with 80% free cash flow conversion. Cash on hand $1.96 billion and gross debt leverage ratio 1.9x. 2026 free cash flow expected ≈ $4.2 billion.
Exceptional EP Performance and PFA Adoption
Global EP organic growth of 35% in Q4 and 73% full-year driven by PFA (Farapulse) adoption. Management cited ~70% PFA penetration for AF ablations in the U.S. and strong uptake of mapping systems and OPAL placements, positioning EP to outpace a forecasted ~15% market growth in 2026.
WATCHMAN Franchise Momentum and Clinical Catalysts
WATCHMAN grew 29% in Q4 and delivered strong double-digit full-year growth across major markets. Over 25,000 patients treated concomitantly. CHAMPION trial accepted as a late breaker at ACC; positive data could expand indicated patients materially (management noted potential expansion from ~5M to ~20M globally if favorable).
Cardiovascular and Interventional Oncology Strength
Cardiovascular segment: Q4 organic growth 16% and full-year organic 21%. Interventional Oncology & Embolization: Q4 organic growth 12% and nearly $1 billion in full-year sales. Drug-eluting technology (Agent DCB) grew >20% for the full year.
Balanced 2026 Guidance and Long-Range Targets
2026 guidance: full-year organic growth 10.0%–11.0%, Q1 organic 8.5%–10.0%. Full-year adjusted EPS guidance $3.43–$3.49 (+12%–14% vs. 2025). Long-range plan reaffirmed: 10%+ annual organic growth (2026–2028) and 150 bps operating margin expansion.
Strategic M&A and Credit Strength
Closed acquisition of Nalu Medical; announced agreements to acquire Valencia Technologies and Penumbra (expected to close in 2026). All three major rating agencies affirmed A-equivalent credit rating; Fitch upgraded outlook to positive.
BSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $91.62 | $75.50 | -17.59% |
Oct 22, 2025 | $99.90 | $103.85 | +3.95% |
Jul 23, 2025 | $103.16 | $107.76 | +4.46% |
Apr 23, 2025 | $95.05 | $98.92 | +4.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Boston Scientific (BSX) report earnings?
Boston Scientific (BSX) is schdueled to report earning on Apr 29, 2026, Before Open (Confirmed).
What is Boston Scientific (BSX) earnings time?
Boston Scientific (BSX) earnings time is at Apr 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BSX EPS forecast?
BSX EPS forecast for the fiscal quarter 2026 (Q1) is 0.79.
